ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2022
Risk factors for dysgeusia during chemotherapy for solid tumors: a retrospective cross-sectional study.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- MASCC/ISOO Clinical Practice Statement: Management of oral complications of targeted therapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Guideline
- Taste and Smell Disorders in Cancer Treatment: Results from an Integrative Rapid Systematic Review.International journal of molecular sciences · 2023Pooled it
- Influence of different photobiomodulation protocols on the prevention of chemotherapy-induced dysgeusia in breast cancer patients treated with Doxorubicin-Cyclophosphamide: a phase III, randomized, triple-blinded non-inferiority clinical trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Trial
- Chemosensory response to Pt-based chemotherapeutics via bitter taste receptors in vitro reveals a new mechanism for bitter taste disorders.Scientific reports · 2026Article
- Risk factors for dyseugia during chemotherapy in breast cancer women: A cohort STROBE-guided.Journal of clinical and experimental dentistry · 2026Review
- Taste alterations in patients with cancer: an overview and recommendations for future research.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Review
- Molecular Targets for Pharmacotherapy of Head and Neck Squamous Cell Carcinomas.Current issues in molecular biology · 2025Review
- Taste Dysfunction in Head and Neck Cancer: Pathophysiology and Clinical Management-A Comprehensive Review.Biomedicines · 2025Review
- The Effect of the Number of Adjuvant Chemotherapy Cycles Following Cancer Surgery on Taste Alteration, Energy Intake, and Life Quality: 6-Month Follow-Up Study.Life (Basel, Switzerland) · 2025Article
- Characterization of Antineoplastic Agents Inducing Taste and Smell Disorders Using the FAERS Database.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Zinc supplementation for dysgeusia in patients with unresectable pancreatic cancer.International journal of clinical oncology · 2024Article
- Smell and Taste Alterations in Patients Receiving Curative or Palliative Chemotherapy-The CONKO 021-ChemTox Trial.Cancers · 2024Article
- Taste and Smell Alterations (TSAs) in Cancer Patients.Diseases (Basel, Switzerland) · 2024Review
- Effectiveness of intraoral stents in reducing oral adverse events during radiotherapy for maxillary or nasal cavity malignant tumors.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Taste alteration and its relationship with nutritional status among cancer patients receiving chemotherapy, cross-sectional study.PloS one · 2024Article
- Development of a Patient-Reported Outcome Measure (PROM) for Dysgeusia During Treatment With Smoothened (SMO) Inhibitors for Basal Cell Carcinomas: The SMO-iD Questionnaire.Dermatology practical & conceptual · 2023Article
- Heterogeneity of vulnerability and taste changes in older cancer patients undergoing chemotherapy: a latent class analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study retrospectively analyzed the risk factors for transchemotherapy dysgeusia.
methodsBefore each chemotherapy cycle, patients were routinely evaluated for the presence/severity of dysgeusia based on the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 scale for adverse effects and graded as follows: 0, no change in taste; 1, altered taste with no impact on eating habits; or 2, altered taste with an impact on eating habits. Information from 2 years of evaluations was collected and patient medical records were reviewed to obtain data on chemotherapy cycle, sex, age, body mass index, body surface area, primary tumor, chemotherapy protocol, and history of head and neck radiotherapy. The X
resultsAmong 7425 total patients, 3047, 2447, and 1931 were evaluated after the first, second, and third chemotherapy cycles, respectively. One-fifth of the patients (19.0%) presented a significant loss of taste, with 1118 (15.0%) showing grade 1 dysgeusia and 442 (6.0%) showing grade 2 dysgeusia. The chemotherapy duration (p < 0.001), female sex (p < 0.001), location of the primary tumor in the uterus (p = 0.008), head and neck (p = 0.012), and testicles (p = 0.011), and use of ifosfamide (p = 0.009), docetaxel (p = 0.001), paclitaxel (p < 0.001), pertuzumab (p = 0.005), bevacizumab (p < 0.001), and dacarbazine (p = 0.002) independently increased the risk of dysgeusia. In head and neck tumors, a previous history of radiotherapy significantly increased the prevalence of dysgeusia (p = 0.017), and the use of cisplatin (p = 0.001) increased this prevalence.
conclusionCycles of chemotherapy, sex, uterine cancer, head and neck tumors, testicular cancer, ifosfamide, docetaxel, paclitaxel, pertuzumab, bevacizumab, and dacarbazine increase the risk of dysgeusia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.